DALLAS, April 2, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Fabry Disease - Pipeline Review, H1 2015" therapeutic market research report of 72 pages with latest updates, data and information to its online business intelligence library.
The report "Fabry Disease - Pipeline Review, H1 2015" report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Fabry disease is an inherited disorder that results from the buildup of a particular type of fat. The primary defect which allows this to occur is the inherited deficiency of the enzyme, alpha galactosidase A, which is normally responsible for the breakdown of globotriaosylceramide. Fabry disease is an inherited disorder. The defective gene is on the X-chromosome, which is one of the two chromosomes that determine an individual's sex.
It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. Companies discussed in this report include Amicus Therapeutics, Inc., Biosidus S.A., Genzyme Corporation, greenovation Biotech GmbH, iBio, Inc., ISU ABXIS Co.,Ltd., JCR Pharmaceuticals Co., Ltd., Neuraltus Pharmaceuticals, Inc., Pharming Group N.V., Protalix BioTherapeutics, Inc., Synageva BioPharma Corp.
Drug Profiles discussed in this report include (migalastat hydrochloride + agalsidase alfa), agalsidase alfa, agalsidase beta biosimilar, agalsidase beta biosimilar, Alpha-Galactosidase, Genz-682452, GZ-402671, JR-051, migalastat hydrochloride, Next Generation biologics for Pompe, Fabry and Hunter, NP-003, PRX-102, Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=314349 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases cover by this report include: Jan 26, 2015: Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium; Jan 08, 2015: Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy Study 011 and Long Term Extension Study; Dec 22, 2014: Amicus Therapeutics to Present Program Updates at 33rd Annual J.P. Morgan Healthcare Conference; Nov 15, 2014: Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology; Oct 19, 2014: Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011; Sep 29, 2014: First GMP-C ompliant Batch of a Biologic Drug Substance from a Moss Expression System Produced for Clinical Use; Aug 20, 2014: Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012; Jun 30, 2014: Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012; Apr 29, 2014: Amicus Therapeutics Announces Positive 12- and 24-Month Data From Phase 3 Fabry Monotherapy Study 011; Feb 12, 2014: Amicus Therapeutics Highlights Data Featured at Lysosomal Disease Network WORLD Symposium 2014.
- The report provides a snapshot of the global therapeutic landscape of Fabry Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fabry Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fabry Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fabry Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fabry Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fabry Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
SOURCE RnR Market Research